URSODESOXYCHOLIC ACID TEVA 250 mg tab pellic,,,URSODESOXYCHOLIC ACID 250 mg tab (URSODESOXYCHOLIC ACID TEVA)

pharmacotherapeutic classification:

Gastro-Entero-Hepatology : Primary biliary cirrhosis ( Ursodeoxycholic acid )
Metabolism - Diabetes - Nutrition - Mucoviscidosis : Liver damage: ursodeoxycholic acid ( Cholelithiasis: bile acid )

ATC classification:

DIGESTIVE TRACT AND METABOLISM : HEPATIC AND BILIARY THERAPY - BILIARY THERAPY : BILE ACIDS AND DERIVATIVES ( URSODESOXYCHOLIC ACID )

Substance
ursodeoxycholic acid

Excipients:

corn starch , sodium lauryl sulfate , povidone , colloidal anhydrous silica , magnesium stearate

colorant (film coating):  titanium dioxide

film coating:  hypromellose , propylene glycol

Excipients with known effect :

NTE without threshold dose:  anhydrous glucose

Presentation

URSODESOXYCHOLIC ACID TEVA 250 mg Cpr pell Plq/20

Cip: 3400922334295

Storage conditions: Before opening: for 36 months

List 1

Approved for Communities

Refund: 65%

Read More

URSODESOXYCHOLIC ACID TEVA 500 mg dry tablet,,,URSODESOXYCHOLIC ACID 500 mg tab (URSODESOXYCHOLIC ACID TEVA)

pharmacotherapeutic classification:

Gastro-Entero-Hepatology : Primary biliary cirrhosis ( Ursodeoxycholic acid )
Metabolism - Diabetes - Nutrition - Mucoviscidosis : Liver damage: ursodeoxycholic acid ( Cholelithiasis: bile acid )

ATC classification:DIGESTIVE TRACT AND METABOLISM : HEPATIC AND BILIARY THERAPY - BILIARY THERAPY : BILE ACIDS AND DERIVATIVES ( URSODESOXYCHOLIC ACID )

Substance
ursodeoxycholic acid

Excipients:

corn starch , colloidal anhydrous silica , povidone , sodium lauryl sulfate , magnesium stearate

film coating:  hypromellose , propylene glycol

colorant (film coating):  titanium dioxide

Excipients with known effect :

NTE without threshold dose:  anhydrous glucose

Presentation

URSODESOXYCHOLIC ACID TEVA 500 mg Cpr dry pell Plq/60

Cip: 3400930203767

Storage conditions: Before opening: for 36 months

List 1

Approved for Communities

Refund: 65%

Read More